Legit Tirzepatide

Tirzepatide Weight Loss: The Trial Evidence | Tirzepatide

The short version

Tirzepatide weight loss numbers are large — larger than any approved weight-management drug has produced in a randomised controlled trial. In SURMOUNT-1, the biggest obesity trial to date for this drug, the highest dose (15 mg once weekly) produced an average loss of 20.9% of body weight over 72 weeks, compared with 3.1% for placebo. That is roughly one-fifth of body mass. In a direct head-to-head comparison against semaglutide in people with obesity without diabetes (SURMOUNT-5, 2025), tirzepatide at maximum tolerated dose lost an average of 20.2% versus 13.7% — a statistically significant difference. These are the headline figures. The full story includes dose-dependent responses (lower doses produce smaller losses), a gradual escalation schedule, mostly gastrointestinal side effects, and a clearly documented weight-regain pattern after stopping. This page reads the weight trial evidence in full.

Tirzepatide weight loss: SURMOUNT-1 results

SURMOUNT-1 was a 72-week, phase 3, double-blind, randomised controlled trial of 2,539 adults with obesity (BMI 30 or greater, or 27 or greater with at least one weight-related complication) and without type 2 diabetes. Participants were randomised to tirzepatide 5 mg, 10 mg, or 15 mg once weekly, or placebo.

Mean body weight changes at week 72 [3]:

  • Tirzepatide 5 mg: -15.0% versus -3.1% placebo
  • Tirzepatide 10 mg: -19.5% versus -3.1% placebo
  • Tirzepatide 15 mg: -20.9% versus -3.1% placebo

All three doses were statistically superior to placebo. The dose-response gradient was clear and consistent. The most common adverse events were gastrointestinal — nausea, diarrhoea, vomiting, constipation — mostly mild to moderate in severity, and most frequent during the dose-escalation phase (the first 20 weeks, during which doses are increased stepwise every four weeks).

The weight reduction observed at 15 mg (approximately one-fifth of initial body weight on average) substantially exceeds what had been seen in prior obesity pharmacotherapy trials, making SURMOUNT-1 a landmark in the incretin pharmacology record.

Tirzepatide vs semaglutide: the head-to-head weight data

SURMOUNT-5 (2025) was a 72-week, phase 3b, open-label, head-to-head randomised controlled trial of 751 adults with obesity but without type 2 diabetes. Participants received the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg) once weekly.

Least-squares mean weight change at week 72 [4]:

  • Tirzepatide: -20.2%
  • Semaglutide: -13.7%

Difference: -6.5 percentage points in favour of tirzepatide (p < 0.001). Tirzepatide also produced a greater reduction in waist circumference and higher proportions of participants reaching weight-loss thresholds of 10%, 15%, 20%, and 25%.

In type 2 diabetes, the same comparison was run in SURPASS-2 (n=1,879, 40 weeks) at fixed doses rather than maximum tolerated. Tirzepatide at all three doses produced greater HbA1c reduction than semaglutide 1 mg (2.30 vs 1.86 percentage points at 15 mg), and greater weight reduction at every dose studied (treatment difference -5.5 kg at 15 mg) [2].

The two head-to-head datasets together — one in diabetes, one in obesity, different dose comparison structures — consistently show tirzepatide producing larger weight reductions than the GLP-1-only reference.

Tirzepatide results across the SURMOUNT programme

Beyond SURMOUNT-1 and SURMOUNT-5, the weight programme includes SURMOUNT-2 (type 2 diabetes with obesity) and SURMOUNT-OSA (obstructive sleep apnea with obesity). SURMOUNT-OSA reported significant reductions in the apnea-hypopnea index alongside weight loss, forming the basis for the sleep apnea indication [14].

SURMOUNT-4 addressed a critical clinical question: what happens when treatment stops? Participants who had lost weight during an initial open-label run-in and then were randomised to continue tirzepatide or switch to placebo regained a substantial proportion of lost weight on placebo, while continuing on tirzepatide produced further loss. A post hoc analysis confirmed that weight regain after stopping was associated with worsening of cardiometabolic markers, including blood pressure, lipids, and glycaemic indices [8][9]. This underscores that tirzepatide weight loss is not a finite course — it is a chronic treatment with ongoing benefit.

Tirzepatide weight loss: what the dose data show

The approved titration schedule in the clinical development programme starts at 2.5 mg subcutaneous once weekly (initiation dose, not a maintenance dose), escalated by 2.5 mg every four weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg [6]. The dose-weight-loss gradient documented in SURMOUNT-1 was monotonic — each dose step up produced meaningfully more weight loss than the step below.

Body composition data from a SURMOUNT-1 DXA substudy found that approximately 25% of the lost weight was lean mass and approximately 75% was fat mass [7]. That lean-mass proportion is comparable to what has been observed with lifestyle intervention and other pharmacotherapy, but the absolute amount of lean mass lost with a -20.9% total weight loss is larger than with smaller-magnitude interventions. The clinical significance of that lean-mass change — specifically, whether it impairs physical function — is still being characterised. Current review-level evidence recommends resistance exercise as a strategy to mitigate lean-mass loss [15].

For what people report — including weight-loss plateaus, appetite suppression, and energy changes that do not appear in trial protocols — the tirzepatide effects page covers the documented real-world reports.